EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Recent developments in Aspergillus fumigatus research: diversity, drugs, and disease

Nicole Kordana iD, Angus Johnson iD, Katherine Quinn iD, Joshua J Obar iD, Robert A Cramer iD

Microbiology and Molecular Biology Reviews · 2025

DOI: 10.1128/mmbr.00011-23 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Microbiology and Molecular Biology Reviews, 2025. Verfasst von Nicole Kordana und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA. Hauptthemen laut MEDLINE: Aspergillus fumigatus, Aspergillosis, Antifungal Agents. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 395 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in modern medical therapies for many previously intractable human diseases have improved patient outcomes. However, successful disease treatment outcomes are often prevented due to invasive fungal infections caused by the environmental mold Aspergillus fumigatus . As contemporary antifungal therapies have not experienced the same robust advances as other medical therapies, defining mechanisms of A. fumigatus disease initiation and progression remains a critical research priority. To this end, the World Health Organization recently identified A. fumigatus as a research priority human fungal pathogen and the Centers for Disease Control has highlighted the emergence of triazole-resistant A. fumigatus isolates. The expansion in the diversity of host populations susceptible to aspergillosis and the complex and dynamic A. fumigatus genotypic and phenotypic diversity call for a reinvigorated assessment of aspergillosis pathobiological and drug-susceptibility mechanisms. Here, we summarize recent advancements in the field and discuss challenges in our understanding of A. fumigatus heterogeneity and its pathogenesis in diverse host populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aspergillus fumigatusAspergillosisAntifungal AgentsHumansDrug Resistance, FungalAnimalsTriazoles

Stichwörter der Autor:innen

Aspergillus fumigatusantifungal drugsfungal pathogenesisfungal virulenceheterogeneity

Substanzen

Antifungal AgentsTriazoles

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.

ORCID-Profile: Nicole Kordana, Angus Johnson, Katherine Quinn, Joshua J Obar, Robert A Cramer

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
  • NHLBI NIH HHS
  • Cystic Fibrosis Foundation (CFF)

Zitieren

APA

Kordana, N., Johnson, A., Quinn, K., Obar, J. J., & Cramer, R. A. (2025). Recent developments in Aspergillus fumigatus research: diversity, drugs, and disease. Microbiology and Molecular Biology Reviews. https://doi.org/10.1128/mmbr.00011-23

Vancouver

Kordana N, Johnson A, Quinn K, Obar JJ, Cramer RA. Recent developments in Aspergillus fumigatus research: diversity, drugs, and disease. Microbiology and Molecular Biology Reviews. 2025. doi:10.1128/mmbr.00011-23

BibTeX
@article{Kordana2025,
  author = {Kordana, Nicole and Johnson, Angus and Quinn, Katherine and Obar, Joshua J and Cramer, Robert A},
  title = {Recent developments in Aspergillus fumigatus research: diversity, drugs, and disease},
  journal = {Microbiology and Molecular Biology Reviews},
  year = {2025},
  doi = {10.1128/mmbr.00011-23}
}
Kostenlos starten →